fbpx

molecules of the month

Belvarafenib

type II RAF dimer kinase inhibitor

oral 450 mg BID, Ph. II in BRAF/RAS cancers

demonstrated activity in NRAS-mut. tumors

Nature, May 5, 2021

Genentech, CA / Hanmi Pharma, KR

Belvarafenib
2 mins read

The Hanmi/Genentech type II RAF kinase inhibitor, belvarafenib, is a potent and selective inhibitor of RAF dimers. GNE-9815 was covered last month, which was used to validate the biology supporting clinical trials of belvarafenib. This Nature article shares first-in-human results of belvarafenib in BRAF(V600E) and RAS-mutated solid tumors, with a few responses already observed in the dose escalation phase. In agreement with hypothesis that a type II kinase inhibitor would more effectively inhibit RAF dimers than approved type 1.5 inhibitors, belvarafenib demonstrates activity in patients who progressed on prior type 1.5 BRAF(V600E) kinase inhibitors (e.g. vemurafenib, dabrafenib) and against NRAS-mutant tumors in which prior inhibitors are ineffective. Additionally, in contrast to the type 1.5 inhibitors, no reports of squamous cell carcinoma (SCC) were observed,…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: